hNET as a target for neuroblastoma nanomedicine

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62156489%3A43210%2F17%3A43912626" target="_blank" >RIV/62156489:43210/17:43912626 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216305:26620/17:PU128359

Výsledek na webu

<a href="https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf" target="_blank" >https://mnet.mendelu.cz/mendelnet2017/mnet_2017_full.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

hNET as a target for neuroblastoma nanomedicine

Popis výsledku v původním jazyce

Chemotherapy often results in various side effects, which can negatively affect health. Neuroblastoma, one of the most common types of childhood cancer, is but one of the examples, where side effects of chemotherapeutic treatment lower the quality of patient&apos;s life. Modern way how to fight that is to enclose cytotoxic drug into some nanocarrier and its targeting to receptors overexpressed in membranes of cancer cells. Apoferritin (Apo), a natural protein cage, is very suitable as a nanocarrier, as it has no toxicity, immune system does not react to it, and drug can easily be loaded into its cavity. We enclosed ellipticine, clinical tested anti-cancer drug, into Apo cavity (creating ApoElli). The percentage of encapsulation was 61 % and size and transmission electron microscopy analysis showed the preserved Apo ~12 nm icosahedral structure after this encapsulation. Then we modified Apo outer surface with in silico-modelled peptides with hNET affinity and tested its toxicity and hemolytic activity. ApoElli modified with anti-hNET peptides was able to internalize into neuroblastoma cells and to deliver the drug. However, it proved to be safe for human RBC, unlike pure ellipticine, which caused observable hemolysis at the same concentration.

Název v anglickém jazyce

hNET as a target for neuroblastoma nanomedicine

Popis výsledku anglicky

Chemotherapy often results in various side effects, which can negatively affect health. Neuroblastoma, one of the most common types of childhood cancer, is but one of the examples, where side effects of chemotherapeutic treatment lower the quality of patient&apos;s life. Modern way how to fight that is to enclose cytotoxic drug into some nanocarrier and its targeting to receptors overexpressed in membranes of cancer cells. Apoferritin (Apo), a natural protein cage, is very suitable as a nanocarrier, as it has no toxicity, immune system does not react to it, and drug can easily be loaded into its cavity. We enclosed ellipticine, clinical tested anti-cancer drug, into Apo cavity (creating ApoElli). The percentage of encapsulation was 61 % and size and transmission electron microscopy analysis showed the preserved Apo ~12 nm icosahedral structure after this encapsulation. Then we modified Apo outer surface with in silico-modelled peptides with hNET affinity and tested its toxicity and hemolytic activity. ApoElli modified with anti-hNET peptides was able to internalize into neuroblastoma cells and to deliver the drug. However, it proved to be safe for human RBC, unlike pure ellipticine, which caused observable hemolysis at the same concentration.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

MendelNet 2017: Proceedings of International PhD Students Conference

ISBN

978-80-7509-529-9

ISSN

—

e-ISSN

neuvedeno

Počet stran výsledku

6

Strana od-do

878-883

Název nakladatele

Mendelova univerzita v Brně

Místo vydání

Brno

Místo konání akce

Brno

Datum konání akce

8. 11. 2017

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

000440194500157